AU2003201810A1 - Method for reducing morbidity and mortality in critically ill patients - Google Patents

Method for reducing morbidity and mortality in critically ill patients

Info

Publication number
AU2003201810A1
AU2003201810A1 AU2003201810A AU2003201810A AU2003201810A1 AU 2003201810 A1 AU2003201810 A1 AU 2003201810A1 AU 2003201810 A AU2003201810 A AU 2003201810A AU 2003201810 A AU2003201810 A AU 2003201810A AU 2003201810 A1 AU2003201810 A1 AU 2003201810A1
Authority
AU
Australia
Prior art keywords
mortality
critically ill
ill patients
reducing morbidity
morbidity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003201810A
Other languages
English (en)
Other versions
AU2003201810A8 (en
Inventor
Josef Georg Heuer
Alexei Kharitonenkov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2003201810A8 publication Critical patent/AU2003201810A8/xx
Publication of AU2003201810A1 publication Critical patent/AU2003201810A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2003201810A 2002-01-15 2003-01-08 Method for reducing morbidity and mortality in critically ill patients Abandoned AU2003201810A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34889002P 2002-01-15 2002-01-15
US60/348,890 2002-01-15
PCT/US2003/000010 WO2003059270A2 (en) 2002-01-15 2003-01-08 Method for reducing morbidity and mortality in critically ill patients

Publications (2)

Publication Number Publication Date
AU2003201810A8 AU2003201810A8 (en) 2003-07-30
AU2003201810A1 true AU2003201810A1 (en) 2003-07-30

Family

ID=23370005

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003201810A Abandoned AU2003201810A1 (en) 2002-01-15 2003-01-08 Method for reducing morbidity and mortality in critically ill patients

Country Status (6)

Country Link
US (1) US20050176631A1 (https=)
EP (1) EP1469880A4 (https=)
JP (1) JP2005519891A (https=)
AU (1) AU2003201810A1 (https=)
CA (1) CA2468610A1 (https=)
WO (1) WO2003059270A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
EP2270163A1 (en) * 2003-12-10 2011-01-05 Eli Lilly and Company Muteins of fibroblast growth factor 21
US7622445B2 (en) 2004-09-02 2009-11-24 Eli Lilly And Company Muteins of fibroblast growth factor 21
KR100854198B1 (ko) 2004-09-02 2008-08-26 일라이 릴리 앤드 캄파니 섬유아세포 성장 인자 21의 뮤테인
EP2540696B1 (en) 2005-02-24 2020-01-01 Diffusion Pharmaceuticals LLC Trans carotenoids, formulation and uses
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
US8034770B2 (en) 2008-06-04 2011-10-11 Amgen Inc. FGF21 polypeptides comprising two or more mutations
CA2739615C (en) 2008-10-10 2017-12-05 Amgen Inc. Fgf21 mutants comprising polyethylene glycol and uses thereof
WO2010129503A1 (en) * 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
WO2010129600A2 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
MX2011013903A (es) * 2009-06-17 2012-05-08 Amgen Inc Polipeptidos quimericos y usos de los mismos.
EP2445339B1 (en) 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Diffusion enhancing compound and its use with a thrombolytic
EP2679234A3 (en) * 2009-12-02 2014-04-23 Amgen Inc. Binding proteins that bind to human FGFR1C, human beta-klotho and both human FGFR1C and human beta-klotho
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
AU2011262361A1 (en) 2010-06-02 2013-01-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
JP2014500248A (ja) 2010-11-05 2014-01-09 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗糖尿病化合物
BR112014014898A2 (pt) 2011-12-22 2020-10-27 Pfizer Inc. processo para purificar uma amostra de anticorpo h38c2, ou variante do mesmo, e composição compreendendo o referido h38c2
CN114805532A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
CA3018550A1 (en) 2016-03-24 2017-09-28 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
SG11202001379WA (en) 2017-09-08 2020-03-30 Bristol Myers Squibb Co Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash)
JP2018135329A (ja) * 2018-02-19 2018-08-30 ディフュージョン・ファーマシューティカルズ・エルエルシー 双極性トランスカロテノイド塩及びそれらの使用
KR20210027426A (ko) 2018-07-03 2021-03-10 브리스톨-마이어스 스큅 컴퍼니 Fgf21 제제
EP3876996A1 (en) 2018-11-05 2021-09-15 Bristol-Myers Squibb Company Method for purifying pegylated protein
EP4087612A1 (en) 2020-01-08 2022-11-16 Bristol-Myers Squibb Company Fgf-21 conjugate formulations
JP2023538533A (ja) 2020-08-07 2023-09-08 ブリストル－マイヤーズ スクイブ カンパニー 線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１
US20240123031A1 (en) 2020-11-25 2024-04-18 Bristol-Myers Squibb Company Methods of treating liver diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2163626A1 (en) * 1999-11-18 2010-03-17 Novartis Vaccines and Diagnostics, Inc. Human FGF-21 gene and gene expression products
US6716626B1 (en) * 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
US20020081663A1 (en) * 2000-01-05 2002-06-27 Conklin Darrell C. Novel FGF homolog ZFGF11
AU2001245535A1 (en) * 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
US20020151496A1 (en) * 2000-12-08 2002-10-17 Bringmann Peter W. Novel fibroblast growth factors
US20040259780A1 (en) * 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity

Also Published As

Publication number Publication date
WO2003059270A2 (en) 2003-07-24
AU2003201810A8 (en) 2003-07-30
US20050176631A1 (en) 2005-08-11
WO2003059270A3 (en) 2003-11-27
EP1469880A2 (en) 2004-10-27
CA2468610A1 (en) 2003-07-24
JP2005519891A (ja) 2005-07-07
EP1469880A4 (en) 2006-04-26

Similar Documents

Publication Publication Date Title
AU2003201810A1 (en) Method for reducing morbidity and mortality in critically ill patients
AU2003222425A1 (en) Device and method for orienting a device in vivo
AU2003244310A1 (en) Inter-authentication method and device
AU2003266718A1 (en) Nanobubble utilization method and device
AU2003217589A1 (en) Patient transfer and transport device
AU2003235876A1 (en) Authoring device and authoring method
AU2003224116A1 (en) Device and method for moistening objects
AU2003216671A1 (en) Device and method for storing information
AU2003267777A1 (en) Method and device for persistent-memory management
AU2003257702A1 (en) Optometric device and optometric method
AU2003252443A1 (en) Curved shape inspection method and device
AU2003268116A1 (en) Method for reducing morbidity and mortality in critically ill patients
AU2002351206A1 (en) Lateral lubistor structure and method
AU2003256526A1 (en) Arrangements and methods for treating a subject
AU2003249420A1 (en) Stereoradiography device and method for the use thereof
AU2003231448A1 (en) Amenity calculating method and device
AU2003216766A1 (en) Method and device for use in micturition studies
AU2003266601A1 (en) Connection method and connection device
AU2003302173A1 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
AU2003266600A1 (en) Connection method and connection device
AU2003215713A1 (en) Circuit and method for use in data compression
AU2003215767A1 (en) Devices for use in medicine
AU2003211198A1 (en) Storage device and storage method
AU2003303257A1 (en) Method and device for storing information
AU2003280332A1 (en) Device and method for connecting objects

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase